Compare SGP & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGP | AMPH |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 971.8M |
| IPO Year | N/A | 2005 |
| Metric | SGP | AMPH |
|---|---|---|
| Price | $21.88 | $18.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $45.00 | $28.38 |
| AVG Volume (30 Days) | 50.8K | ★ 580.8K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | N/A | $4.64 |
| P/E Ratio | ★ N/A | $127.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.15 | $16.65 |
| 52 Week High | $30.56 | $31.26 |
| Indicator | SGP | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 39.14 |
| Support Level | $20.95 | $17.03 |
| Resistance Level | $26.29 | $24.16 |
| Average True Range (ATR) | 1.48 | 0.88 |
| MACD | -0.26 | -0.40 |
| Stochastic Oscillator | 11.65 | 17.60 |
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.